Infectious disease
Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
The decision follows a 14-0 vote among members of an expert panel advising the agency.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
The Centers for Disease Control and Prevention’s vaccine advisory committee meets today to discuss authorizing the Pfizer-BioNTech vaccine in children aged 5 to 11 years.
The FDA informed Moderna that it would need more time to evaluate the company’s Emergency Use Authorization (EUA) submission for its COVID-19 vaccine for adolescents 12 to 17 years of age.
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for children ages 5 to 11.
Yet another busy week for clinical trial news. Here’s a look.
In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.
PRESS RELEASES